scholarly journals In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae with quinolone resistance-associated alterations in GyrA and ParC

1997 ◽  
Vol 40 (3) ◽  
pp. 437-439 ◽  
Author(s):  
T Deguchi
Keyword(s):  
Antimicrobial Activity ◽  
Neisseria Gonorrhoeae ◽  
Quinolone Resistance ◽  
Clinical Isolates ◽  
In Vitro Antimicrobial Activity

In vitro Antimicrobial Activity of Gatifloxacin Compared with Other Quinolones against Clinical Isolates from Cancer Patients

Chemotherapy ◽  
2004 ◽  
Vol 50 (5) ◽  
pp. 214-220 ◽  
Author(s):  
Kenneth V.I. Rolston ◽  
Irfan Vaziri ◽  
Susan Frisbee-Hume ◽  
Harriet Streeter ◽  
Barbara LeBlanc
Keyword(s):  
Antimicrobial Activity ◽  
Cancer Patients ◽  
Clinical Isolates ◽  
In Vitro Antimicrobial Activity

In Vitro Antimicrobial Activity of “Last-Resort” Antibiotics Against Unusual Nonfermenting Gram-Negative Bacilli Clinical Isolates

2012 ◽  
Vol 18 (4) ◽  
pp. 396-401 ◽  
Author(s):  
Herve Jacquier ◽  
Alban Le Monnier ◽  
Etienne Carbonnelle ◽  
Stephane Corvec ◽  
Marina Illiaquer ◽  
...  
Keyword(s):  
Antimicrobial Activity ◽  
Clinical Isolates ◽  
Gram Negative ◽  
In Vitro Antimicrobial Activity

scholarly journals In vitro antimicrobial activity of five essential oils on multi-drug resistant Gram-negative clinical isolates

2016 ◽  
Vol 5 (3) ◽  
pp. 212 ◽  
Author(s):  
Hercules Sakkas ◽  
Panagiota Gousia ◽  
Vangelis Economou ◽  
Vassilios Sakkas ◽  
Stefanos Petsios ◽  
...  
Keyword(s):  
Antimicrobial Activity ◽  
Essential Oils ◽  
Clinical Isolates ◽  
Drug Resistant ◽  
Gram Negative ◽  
In Vitro Antimicrobial Activity

scholarly journals Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China (2014-2018)

2020 ◽  
Author(s):  
Wenjing Le ◽  
Xiaohong Su ◽  
Xiangdi Lou ◽  
Xuechun Li ◽  
Xiangdong Gong ◽  
...  
Keyword(s):  
Neisseria Gonorrhoeae ◽  
Dna Sequencing ◽  
Multidrug Resistant ◽  
Quinolone Resistance ◽  
Clinical Isolates ◽  
Drug Resistant ◽  
Extended Spectrum ◽  
High Level ◽  
Level Resistance

ABSTRACTPreviously, we reported potent activity of a novel spiropyrimidinetrione, zoliflodacin, against N. gonorrhoeae isolates from symptomatic men in Nanjing, China, collected in 2013. Here, we investigated trends of susceptibilities of zoliflodacin in 986 gonococcal isolates collected from men between 2014 and 2018. N. gonorrhoeae isolates were tested for susceptibility to zoliflodacin and seven other antibiotics. Mutations in gyrA, gyrB, parC and parE genes were determined by PCR and DNA sequencing. The MIC of zoliflodacin for N. gonorrhoeae ranged from ≤0.002 to 0.25 mg/L; the overall MIC50s and MIC90s were 0.06 mg/L and 0.125mg/L in 2018, increasing two-fold from 2014. However, the percent of isolates with lower zoliflodacin MICs declined in each year sequentially while the percent with higher MICs increased yearly (P≤0.00001). All isolates were susceptible to spectinomycin but resistant to ciprofloxacin (MIC ≥1 μg/ml); 21.2% (209/986) were resistant to azithromycin (≥1 μg/ml), 43.4% (428/986) were penicillinase-producing (PPNG), 26.9% (265/986) tetracycline-resistant (TRNG) and 19.4% (191/986) were multi-drug resistant (MDR) isolates. Among 143 isolates with higher zoliflodacin MICs (0.125-0.25 mg/L), all had quinolone resistance associated double or triple mutations in gyrA; 139/143 (97.2%) also had mutations in parC. There were no D429N/A and/or K450T mutations in GyrB identified in the 143 isolates with higher zoliflodacin MICs; a S467N mutation in GyrB was identified in one isolate. We report that zoliflodacin has excellent in vitro activity against clinical gonococcal isolates, including those with high-level resistance to ciprofloxacin, azithromycin and extended spectrum cephalosporins.

Sign in / Sign up

Export Citation Format

Share Document